Semi-Supervised KPCA-Based Monitoring Techniques for Detecting COVID-19 Infection through Blood Tests.

This study introduces a new method for identifying COVID-19 infections using blood test data as part of an anomaly detection problem by combining the kernel principal component analysis (KPCA) and one-class support vector machine (OCSVM). This approach aims to differentiate healthy individuals from those infected with COVID-19 using blood test samples. The KPCA model is used to identify nonlinear patterns in the data, and the OCSVM is used to detect abnormal features. This approach is semi-supervised as it uses unlabeled data during training and only requires data from healthy cases. The method's performance was tested using two sets of blood test samples from hospitals in Brazil and Italy. Compared to other semi-supervised models, such as KPCA-based isolation forest (iForest), local outlier factor (LOF), elliptical envelope (EE) schemes, independent component analysis (ICA), and PCA-based OCSVM, the proposed KPCA-OSVM approach achieved enhanced discrimination performance for detecting potential COVID-19 infections. For the two COVID-19 blood test datasets that were considered, the proposed approach attained an AUC (area under the receiver operating characteristic curve) of 0.99, indicating a high accuracy level in distinguishing between positive and negative samples based on the test results. The study suggests that this approach is a promising solution for detecting COVID-19 infections without labeled data.

Deep Generative Learning-Based 1-SVM Detectors for Unsupervised COVID-19 Infection Detection Using Blood Tests.

A sample blood test has recently become an important tool to help identify false-positive/false-negative real-time reverse transcription polymerase chain reaction (rRT-PCR) tests. Importantly, this is mainly because it is an inexpensive and handy option to detect the potential COVID-19 patients. However, this test should be conducted by certified laboratories, expensive equipment, and trained personnel, and 3-4 h are needed to deliver results. Furthermore, it has relatively large false-negative rates around 15%-20%. Consequently, an alternative and more accessible solution, quicker and less costly, is needed. This article introduces flexible and unsupervised data-driven approaches to detect the COVID-19 infection based on blood test samples. In other words, we address the problem of COVID-19 infection detection using a blood test as an anomaly detection problem through an unsupervised deep hybrid model. Essentially, we amalgamate the features extraction capability of the variational autoencoder (VAE) and the detection sensitivity of the one-class support vector machine (1SVM) algorithm. Two sets of routine blood tests samples from the Albert Einstein Hospital, S ao Paulo, Brazil, and the San Raffaele Hospital, Milan, Italy, are used to assess the performance of the investigated deep learning models. Here, missing values have been imputed based on a random forest regressor. Compared to generative adversarial networks (GANs), deep belief network (DBN), and restricted Boltzmann machine (RBM)-based 1SVM, the traditional VAE, GAN, DBN, and RBM with softmax layer as discriminator layer, and the standalone 1SVM, the proposed VAE-based 1SVM detector offers superior discrimination performance of potential COVID-19 infections. Results also revealed that the deep learning-driven 1SVM detection approaches provide promising detection performance compared to the conventional deep learning models.

A Diagnostic Model to Predict SARS-CoV-2 Positivity in Emergency Department Using Routine Admission Hematological Parameters.

Early detection of SARS-CoV-2 in the emergency department (ED) is a crucial necessity, especially in settings of overcrowding: establishing a pre-diagnostic test probability of infection would help to triage patients and reduce diagnostic errors, and it could be useful in resource-limited countries. Here, we established and validated a clinical predictor of infection based on routine admission hematological parameters. The diagnostic model was developed by comparing 85 consecutive patients with symptomatic COVID-19 confirmed by RT-PCR with 85 symptomatic, SARS-CoV-2-negative controls. Abnormal hematological parameters significantly (p < 0.05) associated with SARS-CoV-2 infection were used to derive a "cumulative score" between 0 and 16. The model was validated in an independent cohort of 170 SARS-CoV-2-positive patients. Several routine hematology parameters were significantly (p < 0.05) associated with SARS-CoV-2 infection. A "cumulative score" score ≥7 discriminated COVID-19-postive patients from controls with a sensitivity of 94% and specificity of 100% (p < 0.001). The high sensitivity of the predictive model was confirmed in the prospective validation set, and the cumulative score (i) predicted SARS-CoV-2 positivity even when the first oro-nasopharyngeal swab RT-PCR result was reported as a false negative in both cohorts and (ii) resulted to be independent from disease severity. The cumulative score based on routine blood parameters can be used to predict an early and accurate diagnosis of SARS-CoV-2 infection in symptomatic patients, thereby facilitating triage and optimizing early management and isolation from the COVID-19 free population, particularly useful in overcrowding situations and in resource-poor settings.

Ensemble learning model for diagnosing COVID-19 from routine blood tests.

BACKGROUND AND OBJECTIVES: The pandemic of novel coronavirus disease 2019 (COVID-19) has severely impacted human society with a massive death toll worldwide. There is an urgent need for early and reliable screening of COVID-19 patients to provide better and timely patient care and to combat the spread of the disease. In this context, recent studies have reported some key advantages of using routine blood tests for initial screening of COVID-19 patients. In this article, first we present a review of the emerging techniques for COVID-19 diagnosis using routine laboratory and/or clinical data. Then, we propose ERLX which is an ensemble learning model for COVID-19 diagnosis from routine blood tests. METHOD: The proposed model uses three well-known diverse classifiers, extra trees, random forest and logistic regression, which have different architectures and learning characteristics at the first level, and then combines their predictions by using a second level extreme gradient boosting (XGBoost) classifier to achieve a better performance. For data preparation, the proposed methodology employs a KNNImputer algorithm to handle null values in the dataset, isolation forest (iForest) to remove outlier data, and a synthetic minority oversampling technique (SMOTE) to balance data distribution. For model interpretability, features importance are reported by using the SHapley Additive exPlanations (SHAP) technique. RESULTS: The proposed model was trained and evaluated by using a publicly available data set from Albert Einstein Hospital in Brazil, which consisted of 5644 data samples with 559 confirmed COVID-19 cases. The ensemble model achieved outstanding performance with an overall accuracy of 99.88% [95% CI: 99.6-100], AUC of 99.38% [95% CI: 97.5-100], a sensitivity of 98.72% [95% CI: 94.6-100] and a specificity of 99.99% [95% CI: 99.99-100]. DISCUSSION: The proposed model revealed better performance when compared against existing state-of-the-art studies (Banerjee et al., 2020; de Freitas Barbosa et al., 2020; de Moraes Batista et al., 2020; Soares et al., 2020) [3,22,56,71] for the same set of features employed by them. As compared to the best performing Bayes Net model (de Freitas Barbosa et al., 2020) [22] average accuracy of 95.159%, ERLX achieved an average accuracy of 99.94%. In comparison with AUC of 85% reported by the SVM model (de Moraes Batista et al., 2020) [56], ERLX obtained AUC of 99.77% in addition to improvements in sensitivity, and specificity. As compared with ER-COV model (Soares et al., 2020) [71] average sensitivity of 70.25% and specificity of 85.98%, ERLX model achieved sensitivity of 99.47% and specificity of 99.99%. The ERLX model obtained a considerably higher score as compared with ANN model (Banerjee et al., 2020) [3] in all performance metrics. Therefore, the model presented is robust and can be deployed for reliable early and rapid screening of COVID-19 patients.